Active Ingredient(s):Lumateperone FDA Approved: * December 20, 2019 Pharm Company: *INTRA-CELLULAR THERAPIES INC Category:Antipsychotic
Lumateperone, sold under the brand name Caplyta, is a medication used for the treatment of schizophrenia and bipolar depression. It is a butyrophenone atypical antipsychotic developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb.
The most common side effects include sleepiness and dry mouth.
Lumateperone was approved for medical use in the United States in December 2019, and becam...
* May have multiple approval dates, manufacturers, or labelers.